Matthew V Lorenzi
Overview
Explore the profile of Matthew V Lorenzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Janes M, Zhang J, Li L, Hansen R, Peters U, Guo X, et al.
Cell
. 2018 Jan;
172(3):578-589.e17.
PMID: 29373830
KRAS was recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active...
12.
Karkera J, Cardona G, Bell K, Gaffney D, Portale J, Santiago-Walker A, et al.
Mol Cancer Ther
. 2017 Apr;
16(8):1717-1726.
PMID: 28416604
Fibroblast growth factor receptor (FGFR) genetic alterations are frequently observed in cancer, suggesting that FGFR inhibition may be a promising therapy in patients harboring these lesions. Identification of predictive and...
13.
Perera T, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, et al.
Mol Cancer Ther
. 2017 Mar;
16(6):1010-1020.
PMID: 28341788
Fibroblast growth factor (FGF) signaling plays critical roles in key biological processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer. Genetic alterations in...
14.
Moores S, Chiu M, Bushey B, Chevalier K, Luistro L, Dorn K, et al.
Cancer Res
. 2016 May;
76(13):3942-53.
PMID: 27216193
Non-small cell lung cancers (NSCLC) with activating EGFR mutations become resistant to tyrosine kinase inhibitors (TKI), often through second-site mutations in EGFR (T790M) and/or activation of the cMet pathway. We...
15.
Wan H, Schroeder G, Hart A, Inghrim J, Grebinski J, Tokarski J, et al.
ACS Med Chem Lett
. 2015 Aug;
6(8):850-5.
PMID: 26288683
JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway....
16.
Hart A, Schroeder G, Wan H, Grebinski J, Inghrim J, Kempson J, et al.
ACS Med Chem Lett
. 2015 Aug;
6(8):845-9.
PMID: 26288682
Early hit to lead work on a pyrrolopyridine chemotype provided access to compounds with biochemical and cellular potency against Janus kinase 2 (JAK2). Structure-based drug design along the extended hinge...
17.
Zimmermann K, Sang X, Mastalerz H, Johnson W, Zhang G, Liu Q, et al.
Bioorg Med Chem Lett
. 2015 May;
25(14):2809-12.
PMID: 25987372
The discovery, synthesis, and characterization of 9H-carbazole-1-carboxamides as potent and selective ATP-competitive inhibitors of Janus kinase 2 (JAK2) are discussed. Optimization for JAK family selectivity led to compounds 14 and...
18.
Lin H, Chen M, Rothe K, Lorenzi M, Woolfson A, Jiang X
Oncotarget
. 2014 Sep;
5(18):8637-50.
PMID: 25226617
Imatinib Mesylate (IM) and other tyrosine kinase inhibitor (TKI) therapies have had a major impact on the treatment of chronic myeloid leukemia (CML). However, TKI monotherapy is not curative, with...
19.
Peng S, Creighton C, Zhang Y, Sen B, Mazumdar T, Myers J, et al.
J Transl Med
. 2013 Aug;
11:198.
PMID: 23981300
Background: The patient-derived xenograft (PDX) model is likely to reflect human tumor biology more accurately than cultured cell lines because human tumors are implanted directly into animals; maintained in an...
20.
Curtin J, Lorenzi M
Oncotarget
. 2011 Feb;
1(7):563-577.
PMID: 21317452
Cancer stem cells (CSCs) represent a unique subset of cells within a tumor that possess self-renewal capacity and pluripotency, and can drive tumor initiation and maintenance. First identified in hematological...